Sirtuins Hauv raum Kev Noj Qab Haus Huv Thiab Kab Mob Ⅴ

Mob raum mob thiab fibrosis

Txawm hais tias thawj qhov laj thawj, qhov tshwm sim ntawm yuav luag tag nrho cov kab mob raum mob ntev (CKD) yog cov kab mob loj heev uas yog thawj qhov tshwm sim ntawm pathological. Hauv CKD nas qauv, NAD + biosynthesis tau raug txo qis, qhia tias kev ua haujlwm ntawm SIRTs kuj tseem cuam tshuam, suav nrog cov cuam tshuam rau lawv cov txheej txheem tiv thaiv fibrotic.

Nyem rau Cistanche rau mob raum

SIRT1 qhia tau hais tias yuav txo qis hauv lub raum biopsy cov qauv los ntawm cov neeg mob uas muaj focal segmental glomerulosclerosis. Silencing SIRT1 tuaj yeem ua rau mob fibrosis hauv cov nas nrog unilateral ureteral obstruction (UUO) thaum stimulating SIRT1 los ntawm kev siv tshuaj los yog kev tshuaj ntsuam genetic manipulation tuaj yeem ua rau muaj kev tiv thaiv kab mob thiab txo cov matrix protein ntau ntxiv hauv kev sim ua qauv ntawm kev mob fibrotic nephropathy. Kev ua haujlwm los tiv thaiv fibrotic ntawm SIRT1 muaj feem xyuam rau nws lub peev xwm los tiv thaiv TGF kev taw qhia txoj hauv kev los ntawm kev tswj hwm ntawm Smad proteins. SIRT1 deacetylates Smad3 thiab Smad4, yog li impairing cov transcription ntawm profibrotic noob, nrog rau hom IV collagen, fibronectin, thiab matrix metalloproteinase 7 (MMP7). Cov teebmeem ntxiv los tiv thaiv fibrotic ntawm SIRT1 yog vim nws lub peev xwm los hloov kho endothelial cell muaj nuj nqi. Hauv cov nas, lub hom phiaj tshem tawm ntawm SIRT1 nyob rau hauv lub endothelium ua rau lub vasodilation impaired vim downregulation ntawm matrix metalloproteinase 14 (MMP14), stimulation ntawm HIF2 -Notch1 axis, thiab tso tawm ntawm proteolytic fragments ntawm endothelial glycocalyx. thiab txhawb fibrosis.

SIRT6 kuj tau pom tias muaj kev tiv thaiv ntawm lub raum interstitial fibrosis. Hauv cov nas, SIRT6 tau tswj hwm tom qab fibrotic insult thiab cuam tshuam nrog -catenin. Cov txiaj ntsig tau txuas mus rau tus txhawb nqa ntawm fibrogenic -catenin lub hom phiaj noob thiab tiv thaiv nws cov ntawv sau los ntawm SIRT6-dependent histone deacetylation. Tsis tas li ntawd, SIRT6 overexpression tiv thaiv lub raum interstitial fibrosis nyob rau hauv nas noj cov zaub mov adenine siab los ntawm downregulating homeodomain interacting protein kinase 2 (HIPK2), uas ua rau ntau yam profibrotic pathways. ntawm ntug dej. Nyob rau hauv lub raum tubular hlwb, glycogen synthase kinase 3 (GSK3) phosphorylates SIRT6 los tiv thaiv nws cov proteasomal degradation, yog li tsim cov nyhuv anti-fibrotic.

Mitochondria yog ib qho tseem ceeb pab rau fibrosis hauv nruab nrog cev nrog rau ob lub raum. SIRT3 tau pom tias muaj cov tshuaj tiv thaiv kab mob hauv lub plawv, tab sis me ntsis paub txog nws lub luag haujlwm hauv lub raum fibrosis. Hauv Sirt3- cov nas tsis muaj zog, lub hnub nyoog ntawm lub raum fibrosis tau nce ntxiv, tej zaum yog vim qhov nce TGF signaling thiab GSK3 hyperacetylation, thaum kawg ua rau Smad3 ua kom. Sirt3- cov nas tsis muaj peev xwm tau txo qis Opa1 thiab Mfn1 qib thiab nce qib Drp1, ua rau mitochondrial fission, uas cuam tshuam nrog rau lub raum tsis ua haujlwm thiab fibrosis. Lwm txoj kev tshawb nrhiav pom tias txo SIRT3 qhia tau nrog kev nce mitochondrial acetylation hauv lub raum tubular hlwb thaum lub sij hawm ntxov ntawm lub raum fibrosis. Kev tsom xam acetylome ntawm UUO qauv rau lub raum tubular hlwb qhia tau hais tias SIRT3-kev kho deacetylation ntawm pyruvate dehydrogenase E1 (PDHE1) ntawm lysine 385 plays lub luag haujlwm tseem ceeb hauv metabolic reprogramming cuam tshuam nrog rau lub raum fibrosis nyhuv. Honokiol activates SIRT3 los tiv thaiv UUO-induced raum fibrosis los ntawm kev tswj mitochondrial dynamics thiab NF-κB-TGF- 1-Smad signaling pathway. SIRT3 kuj tau pom tias deacetylate KLF15, tus tswj tsis zoo ntawm extracellular matrix protein synthesis, hauv podocytes. Overexpression ntawm SIRT3 nyob rau hauv endothelial hlwb tiv thaiv cov mob ntshav qab zib-mob fibrosis nyob rau hauv nas nrog ib tug fibrotic phenotype. Conversely, Sirt3 deficiency nyob rau hauv endothelial hlwb induces metabolic reprogramming uas nkoos TGF -Smad{24}} nyob ntawm mesenchymal hloov nyob rau hauv tubular epithelial hlwb.

Sodium-glucose cotransporter 2 (SGLT2) inhibitors yog cov kev kho mob zoo uas txo cov kev loj hlob ntawm CKD hauv tib neeg. Nws tau raug tshaj tawm tias SGLT2 inhibitor canagliflozin restores SIRT3 qhia thiab txhim kho kev hloov pauv ntawm epithelial-rau-mesenchymal hauv cov nas uas muaj mob raum mob hnyav. SGLT2 inhibitors induce tus yam ntxwv qauv ntawm cov txiaj ntsig zoo, suav nrog kev txo qis oxidative kev nyuaj siab, rov qab kho mitochondrial kev noj qab haus huv, txhim kho mitochondrial biogenesis, txo qis pro-inflammatory thiab pro-fibrotic txoj hauv kev, thiab tswj cov cellular thiab lub cev kev ncaj ncees thiab kev ua si. Cov teebmeem renoprotective ntawm SGLT2 inhibitors tuaj yeem raug tshem tawm los ntawm tshwj xeeb inhibiting autophagy thiab AMPK, qhia tias SIRT3 tuaj yeem ua lub luag haujlwm hauv cov txheej txheem tiv thaiv no.

Vascular Calcification

Vascular calcification tshwm sim nyob rau hauv lub intima thiab xov xwm ntawm lub vasculature thiab yog yus muaj los ntawm thickening thiab poob ntawm elasticity ntawm cov leeg nqaij arterial phab ntsa. Qhov ntau ntawm vascular calcification ua rau mob plawv thiab tuag hauv cov neeg mob CKD. Cov txheej txheem ntawm vascular calcification hauv CKD tsis nkag siab tag nrho, thiab kev txhim kho cov phiaj xwm kev kho mob tsis txaus siab. Cov ntaub ntawv tawm tshiab qhia tias SIRTs tuaj yeem ua lub luag haujlwm tseem ceeb hauv kev tsim cov kab mob vascular calcification.

SIRT1 tau raug tshaj tawm tias yuav txo qis hauv aortas ntawm cov nas hnub nyoog, ua rau kev nthuav qhia ntawm ib qho ntawm SASP yam, suav nrog cov pob txha txhawb nqa cov pob txha morphogenetic protein 2 (BMP2) thiab vascular du leeg cell (VSMC)-txhawb ) kev laus. Hauv CKD nas qauv, lub ntuj polyamine spermidine upregulates SIRT1 thiab attenuates vascular calcification.

SIRT6 tau txo qis hauv cov ntaub so ntswg radial los ntawm cov neeg mob CKD thiab vascular calcification. Tsis tas li ntawd, kev tshem tawm ntawm SIRT6 hauv VSMCs exacerbated vascular calcification hauv CKD nas. SIRT6 khi rau thiab deacetylates runt-related transcription factor 2 (Runx2), uas ua lub luag haujlwm hauv kev sib txawv ntawm osteoblast thiab pob txha morphogenesis, ua kom nws cov degradation thiab txwv cov osteogenic transdifferentiation ntawm VSMCs.

Hauv CKD nas qauv, nce SIRT3 protein ntau tuaj yeem txhim kho mitochondrial muaj nuj nqi, inhibit mitochondrial oxidative kev nyuaj siab, thiab txwv VSMC calcification. Cov teebmeem tiv thaiv no yuav cuam tshuam nrog SIRT3 lub peev xwm los tswj AMPK signaling 187.

polycystic raum kab mob

Autosomal-dominant polycystic raum kab mob (ADPKD) yog kab mob caj ces tshwm sim los ntawm polycystin -1 (PKD1) lossis polycystin -2 (PKD2) Ua los ntawm kev hloov pauv, kwv yees li 1 ntawm 400–1,{{8} } cov neeg raug cuam tshuam. ADPKD yog tus cwj pwm los ntawm ntau lub raum raum uas hloov cov ntaub so ntswg hauv lub raum, ua rau lub raum tsis ua haujlwm.

Lub luag haujlwm muaj peev xwm pathogenic ntawm SIRTs hauv ADPKD yog nyob rau theem pib. Txawm li cas los xij, silence lossis pharmacologically inhibiting SIRT1 tau pom tias txo qis kev tsim cov cyst hauv cov nas. Cov teebmeem phem ntawm SIRT1 hauv ADPKD raug ntaus nqi los ntawm nws txoj haujlwm hauv inhibiting retinoblastoma qog suppressor protein (Rb) thiab p53, yog li txhawb kev txuas ntxiv ntawm epithelial cell loj hlob thiab cyst tsim. Raws li cov kev tshawb pom no, kev ua tau zoo ntawm qhov ncauj nicotinamide, ib qho tshuaj tiv thaiv siab ntawm SIRTs, tau sim hauv cov neeg mob ADPKD. Txoj kev tshawb no pom tias cov khoom noj nicotinamide muaj kev nyab xeeb thiab zam tau tab sis tsis muaj txiaj ntsig zoo; tsis muaj qhov sib txawv ntawm qhov siab-hloov tag nrho lub raum ntim hloov ntawm cov nicotinamide thiab cov placebo pawg tom qab 12 lub hlis ntawm kev kho mob.

kab mob autoimmune

Lub luag haujlwm muaj peev xwm ntawm SIRTs hauv cov kab mob autoimmune yog qhov chaw tawm tshiab nrog ob peb cov ntaub ntawv tam sim no. Txawm li cas los xij, kev tshawb fawb txog kev kho mob thiab kev kho mob qhia tau hais tias SIRT1 ua lub luag haujlwm hauv cov kab mob ntawm ntau yam kab mob autoimmune. Cov qib ntawm SIRT1 mRNA thiab cov protein nyob hauv cov zis ntawm cov neeg mob uas muaj tus mob lupus nephritis tau nce siab dua li cov neeg mob hauv kev zam txim thiab cov neeg noj qab haus huv. Tsis tas li ntawd, SIRT1 qhia tau zoo sib xws rau cov tshuaj tiv thaiv ob npaug-stranded DNA (dsDNA) cov tshuaj tiv thaiv hauv cov neeg mob lupus erythematosus uas muaj thiab tsis muaj nephritis. Ib txoj kev tshawb fawb soj ntsuam cov ntshav peripheral los ntawm 367 SLE cov neeg mob thiab 290 cov neeg noj qab haus huv thiab pom tias SIRT1 txhawb nqa qhov sib txawv rs3758391 hloov pauv tus kab mob thiab tias rs3758391 T allele yog qhov muaj feem cuam tshuam rau lupus nephritis. Hauv MRL / lpr nas nquag ua rau lupus nephritis, kev tswj hwm ntawm SIRT1 short-interfering RNA (siRNA) txo cov kab mob kev puas tsuaj, tshuaj tiv thaiv dsDNA qib, thiab raum IgG deposition. SIRT1 tau qhia ntau heev hauv B hlwb tsis paub thiab tuaj yeem tswj hwm cov tshuaj tiv thaiv kab mob los ntawm deacetylating histones thiab non-histones.

Kev laus lub raum

Lub raum muaj kev nkag siab zoo rau cov txheej txheem kev laus thiab ua rau muaj kev cuam tshuam rau kev mob thiab mob ntev thaum peb muaj hnub nyoog. Cov kev tshawb fawb hauv tsev kho mob tau pom tias lub raum SIRT1 kev ua haujlwm txo qis nrog lub hnub nyoog, nrog los ntawm kev poob ntawm cov hlab ntsha NAD + cov pas dej, ua rau muaj zog mitochondrial o thiab cristae puas. Kev txwv caloric txhim kho mitochondrial abnormalities hauv Sirt1- muaj peev xwm tab sis tsis Sirt1- cov nas muaj hnub nyoog tsis muaj zog thiab lub hom phiaj tshem tawm Sirt1 hauv podocytes ua rau lub raum puas thiab cellular senescence hauv cov nas muaj hnub nyoog. Ib yam li ntawd, Sirt1 noob knockout tuaj yeem ua rau ntxov ntxov ntxov ntawm cov hlwb endothelial, thaum kev tswj hwm ntawm Sirt1 activator lossis NAD + precursor nicotinamide mononucleotide tuaj yeem ua rau lub raum elasticity hauv cov nas thaum laus. Kev txwv caloric kuj tuaj yeem ua rau SIRT6 qhia, ua rau tsis muaj zog NF-κB signaling, thiab txhim kho lub raum ua haujlwm hauv cov nas muaj hnub nyoog. Hais txog SIRT3, lub neej ntev-txhim kho phenotype ntawm cov nas uas tsis muaj angiotensin type IA receptor (AT1AR) piv rau qhov qhia ntawm Nampt thiab Sirt3 hauv lub raum tubular hlwb, nrog nce mitochondrial ntom thiab txo oxidative kev nyuaj siab.

Targeting sirtuins

Muab cov txiaj ntsig kev noj qab haus huv uas tau muab los ntawm SIRTs, qhov kev tshawb pom ntawm sirtuin-activating compounds (STACs) yog lub hom phiaj tseem ceeb hauv thaj teb (Table 3). Thawj STAC tau txheeb xyuas yog resveratrol, uas xav tias yuav qhib SIRT1 los ntawm kev ua tus allosteric modulator thiab txo qis KM ntawm NAD + thiab acetylated peptides, txawm hais tias qhov kev ua haujlwm no muaj teeb meem. Ze li ntawm 200 resveratrol kev sim tshuaj nyob rau hauv ntau theem ntawm kev ua tiav. Hauv feem ntau cov kab mob uas tau sim resveratrol, cov kev kho mob muaj qhov tsis zoo. Qhov laj thawj tseem ceeb rau qhov tsis muaj kev tiv thaiv yog qhov txwv bioavailability ntawm resveratrol, uas yog ib qho teeb meem loj rau kev siv tshuaj kho mob ntawm cov tshuaj no. Txhawm rau kov yeej qhov kev txwv no, cov khoom siv hluav taws xob me me tau tsim los txhawb SIRTs nrog kev sib raug zoo dua li resveratrol. Txawm li cas los xij, txoj hauv kev no nyuaj vim tias cov enzyme inhibitors feem ntau yooj yim los tsim dua li cov activators. Enzyme inhibitors feem ntau ua haujlwm los ntawm kev cuam tshuam ncaj qha rau ntawm qhov chaw catalytic, whereas activators xav tau ib qho chaw sib txuas ntawm qhov sib txawv ntawm lub substrate kom ua haujlwm zoo. Txog niaj hnub no, plaub cov khoom siv hluav taws xob STAC, SRT1720, SRT2104, SRT2183, thiab SRT3025, tau pom tias yuav ua rau SIRT1 kev ua ub no thiab txwv tsis pub lub raum puas hauv ntau yam kev sim, thiab SRT2104 thiab SRT3025 tau nkag mus rau kev sim tshuaj. Txog tam sim no, feem ntau ntawm cov kev sim no tau tsim cov txiaj ntsig nruab nrab. Txawm li cas los xij, qee qhov kev sim ntawm SRT2104 tau tshaj tawm cov txiaj ntsig zoo ntawm lipid profile hauv cov neeg mob ntshav qab zib hom 2, daim tawv nqaij histology hauv cov neeg mob psoriasis, thiab lipopolysaccharide-induced o thiab coagulation hauv cov neeg noj qab haus huv. Ntau qhov kev txhawj xeeb txog kev nyab xeeb tau tshwm sim nrog hluavtaws STACs, piv txwv li, SRT3025 tau raug tshaj tawm los ua rau muaj feem cuam tshuam txog kev tuag taus.

Lwm txoj hauv kev los ua kom muaj zog enzymatic ntawm SIRTs yog ntxiv cov molecules me me uas nce qib NAD +, xws li exogenous NAD + lossis nws cov precursors. NAD + bioavailability kuj tuaj yeem nce ntxiv los ntawm kev thaiv NAD + degradation, piv txwv li los ntawm inhibiting NADase CD38. CD38 inhibitor TNB-738 ib txhij khi ob qhov sib txawv CD38 epitopes thiab tuaj yeem cuam tshuam CD38 enzyme kev ua haujlwm hauv vitro, ua rau muaj kev nce hauv intracellular NAD + qib thiab SIRT kev ua haujlwm. Muaj cov ntaub ntawv los ntawm kev sim tshuaj ntsuam xyuas qhia tias kev kho mob tsom rau NAD muaj kev nyab xeeb. Txawm li cas los xij, txoj hauv kev no tsis muaj SIRT isoform selectivity, uas tuaj yeem cuam tshuam nws qhov kev tsim nyog raws li kev kho mob.

Xaus thiab yav tom ntej Outlook

Txij li thaum thawj qhov kev tshawb pom ntawm SIRTs, kev nkag siab ntawm tsev neeg cov protein no tau dhau los ua ntau dua. Thaum cov kev tshawb fawb thawj zaug tsom rau kev txheeb xyuas cov ntsiab lus tseem ceeb rau SIRT enzymatic kev ua si, cov kev tshawb fawb tom ntej tau txhawb lub tswv yim tias SIRT tswj cov kev ua haujlwm ntawm cov hom phiaj cov proteins kom orchestrate kev sib koom tes ntawm lub cev hauv ntau cov txheej txheem ntawm tes, suav nrog cov metabolism, oxidative stress, thiab stimulation, cell survival. , thiab genome stability. Cov ntaub ntawv uas twb muaj lawm qhia tias SIRTs yog qhov tseem ceeb rau kev ntsuas cov plethora ntawm cov kev ntxhov siab hauv cov kab mob metabolically, nrog rau lub raum, cuam tshuam rau lub cev thiab pathophysiology. Kev nkag siab ntau ntxiv ntawm kev tswj hwm txoj hauv kev metabolic thiab tsis-metabolic txoj hauv kev los ntawm SIRT hauv ntau lub raum ntawm tes yuav muab lub sijhawm tshwj xeeb los txheeb xyuas lub hom phiaj tshiab rau kev kho mob ntawm ntau yam kab mob raum. Cov kev cuam tshuam tsom rau SIRT muaj peev xwm zoo hauv kev kho mob raum thiab tiv thaiv kab mob raum muaj hnub nyoog, raws li pom los ntawm cov teebmeem muaj zog ntawm STACs hauv cov qauv kev sim. Hmoov tsis zoo, kev mob siab rau hauv kev tshawb fawb preclinical tau tsuas yog qee qhov me me hauv kev tshawb fawb soj ntsuam. Kev txhais lus ntawm SIRT modulators los ntawm lub rooj ntev zaum mus rau lub tsev kho mob yog cuam tshuam los ntawm qhov tsis muaj cov neeg sib tw xaiv cov sib txuas tsom rau ib tus neeg SIRT subtypes thiab lub zog nruab nrab, txwv bioavailability, thiab tsis zoo pharmacokinetic thiab pharmacodynamic profiles ntawm cov neeg sib tw uas twb muaj lawm. raug thaiv. Cov ntaub ntawv kho mob thaum ntxov ntawm SRT2104 hauv cov kab mob metabolic, psoriasis, thiab mob ua rau muaj kev txhawb zog rau kev tshawb fawb txuas ntxiv mus rau cov tshiab SIRT activators. Yav tom ntej, qhov kev kho mob SIRT-targeted no tuaj yeem siv los ua kom muaj kev noj qab haus huv nruab nrab ntawm tib neeg.

Cistanche kho mob raum li cas?

Cistancheyog ib hom tshuaj suav tshuaj ntsuab siv rau ntau pua xyoo los kho ntau yam mob, suav nrograumkab mob. Nws yog muab los ntawm qhuav stems ntawmCistanchedeserticola, ib tsob nroj nyob rau hauv cov suab puam ntawm Tuam Tshoj thiab Mongolia. Lub ntsiab active Cheebtsam ntawm cistanche yogphenylethanoidglycosides, echinacoside cov tshuaj, thiabacteoside, uas tau pom tias muaj txiaj ntsig zoo rau lub raum kev noj qab haus huv.

Kab mob raum, tseem hu ua kab mob raum, yog ib yam mob uas lub raum ua haujlwm tsis zoo. Qhov no tuaj yeem ua rau muaj cov khoom pov tseg thiab cov co toxins hauv lub cev, ua rau muaj ntau yam tsos mob thiab teeb meem. Cistanche tuaj yeem pab kho mob raum ase los ntawm ntau lub tswv yim.

Ua ntej, cistanche tau pom tias muaj cov nyhuv diuretic, txhais tau tias nws tuaj yeem ua rau cov zis ntau ntxiv thiab pab tshem tawm cov khoom pov tseg ntawm lub cev. Qhov no tuaj yeem pab txo lub nra ntawm lub raum thiab tiv thaiv kev tsim cov co toxins. Los ntawm kev txhawb nqa diuresis, cistanche kuj tseem tuaj yeem pab txo qis ntshav siab, ib qho teeb meem ntawm cov kab mob raum.

Ntxiv mus, cistanche tau pom tias muaj cov teebmeem antioxidant. Kev ntxhov siab oxidative, tshwm sim los ntawm qhov tsis sib xws ntawm kev tsim cov dawb radicals thiab lub cev tiv thaiv antioxidant, ua lub luag haujlwm tseem ceeb hauv kev mob raum. ies pab neutralize dawb radicals thiab txo Oxidative kev nyuaj siab, yog li tiv thaiv lub raum los ntawm kev puas tsuaj. Cov phenylethanoid glycosides pom hauv cistanche tau tshwj xeeb hauv kev tshem tawm cov dawb radicals thiab inhibiting lipid peroxidation.

Tsis tas li ntawd, cistanche tau pom tias muaj cov nyhuv anti-inflammatory. Kev mob yog lwm yam tseem ceeb hauv kev loj hlob thiab kev loj hlob ntawm cov kab mob raum. Cistanche's anti-inflammatory zog pab txo cov zus tau tej cov pro-inflammatory cytokines thiab inhibit qhov ua kom o yuav tsum tau txoj kev, yog li alleviating o nyob rau hauv lub raum.

Tsis tas li ntawd, cistanche tau pom tias muaj cov teebmeem immunomodulatory. Hauv kab mob raum, lub cev tiv thaiv kab mob tuaj yeem ua rau tsis zoo, ua rau muaj kev mob ntau dhau thiab cov ntaub so ntswg puas. Cistanche pab tswj lub cev tiv thaiv kab mob los ntawm kev hloov kho kev tsim khoom thiab kev ua haujlwm ntawm lub cev tiv thaiv kab mob, xws li T hlwb thiab macrophages. Txoj cai tiv thaiv kab mob no pab txo qhov mob thiab tiv thaiv kev puas tsuaj ntxiv rau lub raum.

Ntxiv mus, cistanche tau pom los txhim kho lub raum kev ua haujlwm los ntawm kev txhawb nqa kev tsim kho ntawm lub raum hlab nrog cov hlwb. Lub raum tubular epithelial hlwb ua lub luag haujlwm tseem ceeb hauv kev pom thiab rov nqus cov khoom pov tseg thiab electrolytes. Hauv kab mob raum, cov hlwb no tuaj yeem raug puas tsuaj, ua rau lub raum ua haujlwm puas. Cistanche lub peev xwm los txhawb kev tsim kho ntawm cov hlwb no pab kho lub raum kom zoo thiab txhim kho lub raum tag nrho.

Ntxiv nrog rau cov kev cuam tshuam ncaj qha rau lub raum, cistanche tau pom tias muaj txiaj ntsig zoo rau lwm yam kabmob thiab lub cev hauv lub cev. Txoj hauv kev zoo rau kev noj qab haus huv no tseem ceeb tshwj xeeb hauv cov kab mob raum, vim tias tus mob feem ntau cuam tshuam rau ntau lub cev thiab lub cev. che tau pom tias muaj kev tiv thaiv rau lub siab, lub plawv, thiab cov hlab ntsha, uas feem ntau cuam tshuam los ntawm kab mob raum. Los ntawm kev txhawb nqa kev noj qab haus huv ntawm cov kabmob no, cistanche pab txhim kho lub raum tag nrho thiab tiv thaiv kev mob ntxiv.

Hauv kev xaus, cistanche yog cov tshuaj suav tshuaj ntsuab siv rau ntau pua xyoo los kho mob raum. Nws cov active Cheebtsam muaj diuretic, antioxidant, anti-inflammatory, immunomodulatory, thiab regenerative teebmeem, uas pab txhim kho lub raum ua haujlwm thiab tiv thaiv ob lub raum los ntawm kev puas tsuaj ntxiv. , cistanche muaj txiaj ntsig zoo rau lwm yam kabmob thiab lub cev, ua rau nws txoj hauv kev zoo rau kev kho mob raum.